☆ 4.6 Article

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2middot57 million people in Scotland (EAVE II): a prospective cohort study

LANCET RESPIRATORY MEDICINE (2020)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

COVID-19 vaccines: where we stand and challenges ahead

Guido Forni et al.

Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Katie J. Ewer et al.

Summary: A single dose of the ChAdOx1 nCoV-19 vaccine can induce favorable immune responses that may help control or prevent SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Covid-19 vaccination: What’s the evidence for extending the dosing interval?

Gareth Iacobucci et al.

BMJ-British Medical Journal (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?

John F. R. Robertson et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Virology

Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection

Federico Gobbi et al.

Summary: Individuals who previously contracted SARS-CoV-2 are expected to have a more rapid and sustained immune response to COVID-19 vaccines, with markedly higher titers of neutralizing antibodies compared to natural infection. A single dose of the vaccine may be sufficient to induce an effective response in previously infected individuals.

VIRUSES-BASEL (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Hospital admissions due to COVID-19 in Scotland after one dose of vaccine

Natalie Dean

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Eleftheria Vasileiou et al.

Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.

LANCET (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Delaying the second dose of covid-19 vaccines

Dominic Pimenta et al.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data

Colin R. Simpson et al.

BMJ OPEN (2020)

Add to Collection

Article Medicine, General & Internal

Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10131 US Veterans With SARS-CoV-2 Infection

George N. Ioannou et al.

JAMA NETWORK OPEN (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Medicine, General & Internal

The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement

Eric I. Benchimol et al.

PLOS MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Erik von Elm et al.

LANCET (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.